In this webinar, we focus on the scalability of donor starting material to support the growth and commercialization of allogeneic therapies. Throughout this discussion, we answer these questions on scalability and consistency in the allogeneic supply chain: What are the major gaps currently in the industry? How can we gain a better understanding of what…
Navigating international differences in regulations for cellular starting material is complex. This is particularly true because the rapid advancement of the industry sometimes precedes regulatory guidance. When you’re procuring cellular starting material or distributing a cell or gene therapy product across international borders, you must consider the country or regional requirements at play and where…
Learn why cord blood may be an excellent starting material for your therapy Cord blood has been used to provide life-saving treatments to patients for decades, but its full potential has not yet been tapped. Learn about scalability considerations when using cord blood. During this hour long on-demand webinar, our panelists discuss: Why it’s essential…
To ensure safe, high-quality Advanced Therapy Medicinal Products (ATMPs) are delivered to patients, procurement activities must be standardized when possible. Standardization also supports efficiency and reduces the risk for error while meeting regulatory and accreditation requirements. Download the UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture for insights…
A joint venture between the European Society of Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), the CAR-T Cell Handbook offers clinical care applications for health care professionals in the EU that treat patients with CAR-T cell therapies. Download the guide for insights into many aspects of CAR-T cell therapies including: The…
Off-the-shelf cord blood units (CBUs) are a rich source of cells for use in the development of allogeneic cell and gene therapies. However, CBUs with the characteristics you need may be spread across multiple cord blood banks. Understanding which cord blood banks have the CBUs that meet your requirements is a challenge. And qualifying and…
Considerations for developing scalable and efficient collection network processes The decisions you make when selecting apheresis centers to collect source material for your cell or gene therapy impact your ability to efficiently scale your processes. When your processes and protocols differ from those at an apheresis center, delays can occur. Following best practices can help.…
The ONE Forum 2021: On-demand session As cell and gene therapies continue to progress at a rapid pace, apheresis and collection centers face the challenges of maintaining collection capacity to keep up with demand, while ensuring high quality levels. This session focuses on capability and capacity considerations to support these emerging therapies, standardization strategies and…
The ONE Forum 2021: On-demand session Over the last several years, there has been increasing global investment in the development of novel allogeneic cellular therapies. A recent study published by Nature Reviews Drug Discovery estimates that in 2021 over 400 novel allogeneic cellular therapies are under development across the globe, many of which are focused…